ArticleJournal of neuroscience research2009
Cannabinoid modulation of cortical adrenergic receptors and transporters.
Article in Journal of neuroscience research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Formoterol dynamically alters endocannabinoid tone in the periaqueductal gray inducing headache.The journal of headache and pain · 2024Article
- Cortical adrenoceptor expression, function and adaptation under conditions of cannabinoid receptor deletion.Experimental neurology · 2017Article
- The effects of synthetic cannabinoids on executive function.Psychopharmacology · 2017Article
- Cannabis Abusers Show Hypofrontality and Blunted Brain Responses to a Stimulant Challenge in Females but not in Males.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Article
- Repeated administration of a synthetic cannabinoid receptor agonist differentially affects cortical and accumbal neuronal morphology in adolescent and adult rats.Brain structure & function · 2016Article
- Species differences in cannabinoid receptor 2 and receptor responses to cocaine self-administration in mice and rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Article
- Cannabinoid modulation of alpha2 adrenergic receptor function in rodent medial prefrontal cortex.The European journal of neuroscience · 2014Article
- Endocannabinoid signaling in the etiology and treatment of major depressive illness.Current pharmaceutical design · 2014Review
- Interaction between Antagonist of Cannabinoid Receptor and Antagonist of Adrenergic Receptor on Anxiety in Male Rat.Basic and clinical neuroscience · 2014Article
- Do cannabinoids exhibit a tyramine-like effect?Naunyn-Schmiedeberg's archives of pharmacology · 2013Article
- Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.Neuroscience · 2013Review
- Neonatal DSP-4 treatment modifies antinociceptive effects of the CB1 receptor agonist methanandamide in adult rats.Neurotoxicity research · 2013Article
- Functional diversity on synaptic plasticity mediated by endocannabinoids.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2012Review
- Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders.Progress in neuro-psychopharmacology & biological psychiatry · 2012Review
- The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity.Journal of neurochemistry · 2011Review
- Cannabinoid modulation of limbic forebrain noradrenergic circuitry.The European journal of neuroscience · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
We previously reported that administration of the synthetic cannabinoid agonist WIN 55,212-2 causes an increase in norepinephrine (NE) efflux in the frontal cortex (FC). The present study examined the expression levels of alpha2- and beta1-adrenergic receptors (ARs) as well as the norepinephrine transporter (NET) in the FC of rats following exposure to WIN 55,212-2. Rats received systemic injection of WIN 55,212-2 (3 mg/kg) acutely or for 7 days. Another group of rats received repeated WIN 55,212-2 treatment followed by a period of abstinence. Control rats received vehicle injections. Rats were euthanized 30 min after the last WIN 55,212-2 injection, the FC was microdissected, and protein extracts were probed for alpha2-AR, beta1-AR, and NET. Results showed that beta1-AR expression was significantly decreased following repeated WIN 55,212-2 treatment but significantly increased following a period of abstinence. alpha2-AR expression showed no significant change in all groups examined. NET expression was significantly decreased following acute WIN 55,212-2 treatment, with no changes following chronic administration or a period of abstinence. Alterations in NET may arise from modulation of cannabinoid receptors (CB1) that are localized to noradrenergic axon terminals as we demonstrate colocalization of CB1 receptor and NET in the same cortical axonal processes. The present findings support significant alterations in adrenergic receptor and NET expression in the FC after WIN 55,212 exposure that may underlie the reported changes in attention, cognition, and anxiety commonly observed after cannabinoid exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.